Skip to main content

Table 2 Comparison between Quality Effect Model and the Random Effect Model results

From: Prevalence of BRCA mutations among hereditary breast and/or ovarian cancer patients in Arab countries: systematic review and meta-analysis

 

Quality effect model

Random effect model

No. of studies (patients)

Prevalence (CI 95%)

I2%

No. of studies (patients)

Prevalence (CI 95%)

I2%

All eligible studies

 

14 (917)

20% (7–36%)

94.6%

14 (917)

63% (17–44%)

94.6%

Risk of Bias

 

Low ROB

6 (604)

11% (1–27%)

94.7%

6 (604)

66% (4–31%)

94.7%

Moderate ROB

8 (313)

40% (21–60%)

87.1%

2 (313)

63% (26–59%)

87.1%

Studies with good external validity

3 (374)

5% (0–14%)

85.5%

3 (374)

49% (1–16%)

85.5%

Gene mutations

 

Both BRCA1 and BRCA2

7 (477)

34% (18–52%)

93.2%

7 (477)

78% (22–56%)

93.2%

BRCA1

11 (684)

19% (7–36%)

92.8%

11 (684)

59% (15–42%)

92.8%

BRCA2

6 (488)

27% (16–40%)

87.4%

6 (488)

75% (18–42%)

87.4%

Target population

 

HBOC

3 (348)

7% (0–20%)

91.8%

3 (348)

55% (0–25%)

91.8%

HBC

11 (569)

32% (18–47%)

90.8%

10 (550)

65% (23–50%)

90.8%

HOC

1 (192)

2% (0–5%)

0

1 (192)

33% (0–5%)

0

Geographic Location

 

Levant

4 (240)

28% (11–49%)

87.9%

4 (240)

63% (13–49%)

87.9%

GCC

2 (142)

22% (0–58%)

93.9%

2 (142)

24% (0–56%)

93.9%

North Africa

8 (535)

16% (0–43%)

96.2%

8 (535)

64% (11–54%)

96.2%

Sample size

 

< 100

12 (603)

29% (16–44%)

89.9%

12 (603)

62% (21–48%)

89.9%

≥100

2 (314)

5% (0–16%)

91.4%

2 (314)

52% (0–17%)

91.4%

Year of recruitment

 

≤2011

10 (467)

25% (8–47%)

93.1%

10 (467)

60% (17–52%)

93.1%

2012–2018

5 (572)

13% (1–31%)

95.6%

5 (572)

71% (5–37%)

95.6%

Type of mutation

 

Deleterious

8 (532)

26% (11–44%)

93.6%

8 (532)

71% (17–49%)

93.6%

Deleterious and VUS

2 (266)

10% (0–100%)

98.8%

2 (266)

73% (0–85%)

98.8%

Deleterious, VUS, and Polymorphisims

4 (119)

20% (4–43%)

72.4%

4 (119)

46% (7–57%)

85.0%